← Back to news
S

Seeking Alpha: News

Greenfire Resources reports Q1 results

B

Equinor reports mixed Q1 results; reaffirms FY26 outlook

B

Azenta misses top-line and bottom-line estimates; updates FY26 outlook

S

Archrock misses top-line and bottom-line estimates; reaffirms FY26 outlook

S

Flex beats top-line and bottom-line estimates; gives Q1 and FY27 outlook

S

Jeff Bezos shakes up Blue Origin staff incentives ahead of SpaceX IPO: FT

S

Dave outlines 2026 revenue of $710M-$720M and adjusted EPS of $16.25-$16.75 while testing Dave Flex

S

Joby outlines $105M-$115M 2026 revenue guidance as eIPP agreements expected in Q3

S

Arcus outlines PEAK-1 full enrollment by year-end 2026 with cash runway into 2H 2028

S

Omnicom declares $0.80 dividend

S

MarketWise declares $0.25 dividend and special cash dividend of $0.20 a share

S

Suro Capital outlines July 1 Neostellar rebrand, backed by $20M Magnetar investment

S

Avalo Therapeutics prices $375M public offering; shares jump

S

Enact Holdings raises quarterly dividend by 14% to $0.24/share

S

Marqeta expects $15M GAAP net income in 2026 while maintaining 12%-14% net revenue growth outlook

S

YieldMax® Semiconductor Portfolio Option Income ETF declares $0.6024 dividend

S

YieldMax® AI & Tech Portfolio Option Income ETF declares $0.3343 dividend

S

YieldMax® Universe Fund of Option Income ETFs declares $0.0824 dividend

S

YieldMax® Magnificent 7 Fund of Option Income ETFs declares $0.1801 dividend

S

YieldMax Ultra Option Income Strategy ETF declares $0.3995 dividend

S

YieldMax Ultra Short Option Income Strategy ETF declares $0.302 dividend

S

YieldMax® S&P 500 0DTE Covered Call ETF declares $0.2056 dividend

S

YieldMax® R2000 0DTE Covered Call ETF declares $0.2391 dividend

S

Ashland raises quarterly dividend by 1.2% to $0.42/share

B

Russel Metals raises quarterly dividend by 2.3% to CAD 0.44/share

B

Triple Flag Precious Metals declares $0.0575 dividend

B

Diversified Royalty declares CAD0.02375 dividend

B

Olympia Financial Group Inc. declares CAD 0.60 dividend

B

American Coastal outlines $150M-$200M excess capital and lifts reinsurance exhaustion point to over $1.6B

B

Veeco outlines $740M-$800M FY2026 revenue outlook while planning 10x SPECTOR capacity expansion by early '27

B

Hercules Capital anticipates $350M-$500M Q2 prepayments while targeting 12%-12.5% core yield

S

Ferguson Enterprises Inc. declares $0.89 dividend

S

Atkore declares $0.33 dividend

S

Tempus AI targets $1.59B-$1.6B revenue and about $65M adjusted EBITDA in 2026, backed by Merck collaboration

S

LoanDepot forecasts $5.75B-$7.75B in Q2 lock volume as 5x5 HomeLoan ramps

S

Lumentum anticipates $960M-$1.01B Q4 FY2026 revenue while targeting $2B quarterly revenue goal

S

Carlsmed raises FY 2026 revenue outlook to $72M-$77M as CMS proposes new MS-DRGs for aprevo lumbar

S

Emerson forecasts $6.45 to $6.55 EPS as it updates 2026 sales growth to 4.5% amid Middle East disruption

S

Finance of America projects 2026 adjusted EPS of $4.50-$5.00 while maintaining $2.8B-$3.1B funded volume outlook

S

MNTN raises FY 2026 revenue outlook to $347M-$357M with Q2 revenue seen at $81M-$83M

S

Arista outlines 27.7% 2026 revenue growth to $11.5B while targeting $3.5B in AI fabric sales

S

SSR Mining anticipates Copler sale close before end of Q3 2026 with $1.5B cash proceeds

S

Alphatec forecasts $882M 2026 revenue while keeping adjusted EBITDA at $134M

S

Cytokinetics outlines $830M-$870M 2026 operating expense range while advancing MYQORZO Germany launch

S

Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close

S

GRAIL signals 22%-32% 2026 Galleri sales growth while starting Epic Aura integrations

S

Bright Horizons reaffirms 2026 adjusted EPS of $4.90 to $5.10 while raising Back-Up Care growth outlook to 12% to 14%

S

AMC forecasts 2026 box office could be $500M-$1.2B bigger than 2025 as it launches Arena 1 in 300+ theaters

S

Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3

S

Adaptive Biotechnologies raises 2026 MRD revenue view to $260M-$270M while targeting positive adjusted EBITDA and free cash flow by end of 2026

S